Context Therapeutics Reports First Quarter 2024 Operating and Financial Results tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ I-Mab , a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated.
05.04.2024 - Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that .
Company presentation and fireside chat on April 11th at 11:45 a.m. ETCAMBRIDGE, Mass., April 05, 2024 Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class.
NEW HAVEN, Conn., April 4, 2024 /PRNewswire/ Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic.